Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures Rapport presents new data on the linear relationship between a seizure biomarker used in the company's RAP-219 POC trial and clinical seizures.

Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update Rapport Therapeutics announces financial results for Q2 2024 and provides a business update, including progress on its precision neuroscience pipeline